![]() | Name | Last modified | Size | Description |
---|---|---|---|---|
![]() | Parent Directory | - | ||
![]() | vemurafenib.pdf | 2022-12-01 19:39 | 368K | |
![]() | vandetanib.pdf | 2022-12-01 19:39 | 249K | |
![]() | tumori-neuroendocrine.pdf | 2022-12-01 19:39 | 370K | |
![]() | trastuzumab-non-metastatic.pdf | 2022-12-01 19:38 | 332K | |
![]() | trastuzumab-metastatic.pdf | 2022-12-01 19:38 | 320K | |
![]() | trastuzumab-emtansina.pdf | 2022-12-01 19:39 | 333K | |
![]() | trabectedina.pdf | 2022-12-01 19:39 | 336K | |
![]() | tivozanib.pdf | 2022-09-15 12:14 | 474K | |
![]() | sunitinib.pdf | 2022-12-01 19:38 | 349K | |
![]() | sorafenib.pdf | 2022-12-01 19:38 | 362K | |
![]() | ribociclib.pdf | 2022-12-01 19:38 | 330K | |
![]() | regoafenib.pdf | 2022-12-01 19:39 | 362K | |
![]() | ramucirumab.pdf | 2022-09-15 12:14 | 327K | |
![]() | pertuzuzumab.pdf | 2022-12-01 19:39 | 529K | |
![]() | pertuzumab-trastuzumab.pdf | 2022-09-15 12:14 | 483K | |
![]() | pemetrexed.pdf | 2022-12-01 19:38 | 347K | |
![]() | pembrolizumab.pdf | 2022-12-01 19:39 | 653K | |
![]() | pegfilgrastim.pdf | 2022-12-01 19:38 | 378K | |
![]() | pazopanib.pdf | 2022-12-01 19:39 | 367K | |
![]() | panitumumab.pdf | 2023-02-10 09:22 | 332K | |
![]() | palbociclib.pdf | 2022-12-01 19:38 | 332K | |
![]() | osimertinib.pdf | 2022-09-15 12:14 | 325K | |
![]() | olaparib.pdf | 2022-09-15 12:14 | 418K | |
![]() | nivolumab.pdf | 2022-12-01 19:39 | 611K | |
![]() | nivo-ipi.pdf | 2022-12-01 19:39 | 489K | |
![]() | lonsurf.pdf | 2022-12-01 19:39 | 344K | |
![]() | leuprorelina.pdf | 2022-12-01 19:38 | 384K | |
![]() | lapatinib.pdf | 2022-12-01 19:39 | 299K | |
![]() | irinotecan-onyvide.pdf | 2022-12-01 19:38 | 341K | |
![]() | ipilimumab.pdf | 2022-12-01 19:39 | 327K | |
![]() | interferon-alfa-2a.pdf | 2022-12-01 19:38 | 316K | |
![]() | imatinib.pdf | 2022-12-01 19:38 | 337K | |
![]() | goserelina.pdf | 2022-12-01 19:38 | 358K | |
![]() | gefitinib.pdf | 2022-12-01 19:39 | 384K | |
![]() | fulvestrant.pdf | 2022-12-01 19:38 | 341K | |
![]() | everolimus.pdf | 2022-09-15 12:14 | 264K | |
![]() | everolimus-afinitor.pdf | 2022-12-01 19:39 | 328K | |
![]() | erlotinib.pdf | 2022-12-01 19:38 | 332K | |
![]() | epoetine.pdf | 2022-12-01 19:38 | 339K | |
![]() | enzalutamida.pdf | 2022-12-01 19:38 | 351K | |
![]() | durvalumab.pdf | 2022-12-01 19:39 | 600K | |
![]() | durere-cronica-cancer.pdf | 2022-12-01 19:38 | 358K | |
![]() | dabrafenib.pdf | 2022-12-01 19:38 | 341K | |
![]() | dabrafenib-trametinib.pdf | 2022-12-01 19:38 | 363K | |
![]() | cyproteron.pdf | 2022-12-01 19:38 | 224K | |
![]() | crizotinib.pdf | 2022-12-01 19:39 | 254K | |
![]() | cetuximab.pdf | 2022-12-01 19:38 | 359K | |
![]() | ceritinib.pdf | 2022-12-01 19:38 | 267K | |
![]() | cemiplimab.pdf | 2022-12-01 19:39 | 581K | |
![]() | cabozantinib.pdf | 2022-09-15 12:14 | 416K | |
![]() | cabazitaxel.pdf | 2022-12-01 19:39 | 338K | |
![]() | bevacizumab.pdf | 2022-12-01 19:38 | 411K | |
![]() | axitinib.pdf | 2022-12-01 19:39 | 331K | |
![]() | avelumab.pdf | 2022-09-15 12:14 | 372K | |
![]() | atezolizumab.pdf | 2022-09-15 12:14 | 557K | |
![]() | apalutamida.pdf | 2022-12-01 19:38 | 536K | |
![]() | antiemetice.pdf | 2022-12-01 19:39 | 388K | |
![]() | alectinib.pdf | 2022-12-01 19:38 | 355K | |
![]() | aflibercept.pdf | 2022-12-01 19:38 | 331K | |
![]() | afatinib.pdf | 2022-12-01 19:39 | 334K | |
![]() | acid-zoledronic.pdf | 2022-12-01 19:38 | 270K | |
![]() | acid-ibandronic.pdf | 2022-12-01 19:38 | 278K | |
![]() | acid-clodronic.pdf | 2022-12-01 19:39 | 272K | |
![]() | abiraterona.pdf | 2022-12-01 19:38 | 355K | |
![]() | abemaciclib.pdf | 2022-12-01 19:38 | 344K | |
![]() | TEV.pdf | 2022-12-01 19:39 | 352K | |